Marine Sivignon
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Cost effectiveness and public health impact of PCV20 among adults in France.
Journal: BMC public health
Published: March 13, 2026
Cost-effectiveness of adjuvant alectinib in the treatment of patients with resected stage IB-IIIA ALK-positive non-small lung cancer in France, based on the ALINA study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 19, 2025
Cost-Effectiveness Analysis of Second-Line Lisocabtagene Maraleucel in the Treatment of Refractory or Relapsed Large B-Cell Lymphoma.
Journal: European journal of haematology
Published: October 09, 2025
Cost-Effectiveness and Public Health Impact of Newborn Screening for Spinal Muscular Atrophy in France.
Journal: Applied health economics and health policy
Published: July 25, 2025
A Cost-Effectiveness Analysis of the Switch to 20-Valent Pneumococcal Conjugate Vaccine from Lower-Valent Pneumococcal Conjugate Vaccines in the French Pediatric Population.
Journal: Infectious diseases and therapy
Published: May 23, 2025
Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Chronic Kidney Disease in France, Based on the EMPA-KIDNEY Clinical Trial.
Journal: Clinical drug investigation
Published: October 01, 2024
Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
Journal: Advances in therapy
Published: September 08, 2022
Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease.
Journal: Journal of market access & health policy
Published: June 17, 2022
Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.
Journal: PloS one
Published: May 14, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026